The human cationic host defense peptide LL‐37 mediates contrasting effects on apoptotic pathways in different primary cells of the innate immune system
暂无分享,去创建一个
T. S. Wilkinson | R. Hancock | C. Haslett | A. J. Simpson | C. Cosseau | D. Bowdish | T. Wilkinson | P. Barlow | Peter G. Barlow | Yuexin Li | Y. Lau | Donald J. Davidson
[1] K. Rabe,et al. Human Cathelicidin LL-37 Is a Chemoattractant for Eosinophils and Neutrophils That Acts via Formyl-Peptide Receptors , 2006, International Archives of Allergy and Immunology.
[2] R. Hancock,et al. Apoptosis of airway epithelial cells: human serum sensitive induction by the cathelicidin LL-37. , 2006, American journal of respiratory cell and molecular biology.
[3] I. Nagaoka,et al. An Antimicrobial Cathelicidin Peptide, Human CAP18/LL-37, Suppresses Neutrophil Apoptosis via the Activation of Formyl-Peptide Receptor-Like 1 and P2X71 , 2006, The Journal of Immunology.
[4] Fiona S. L. Brinkman,et al. Modulation of the TLR-Mediated Inflammatory Response by the Endogenous Human Host Defense Peptide LL-371 , 2006, The Journal of Immunology.
[5] William G. Cheadle,et al. Endotoxin Inhibits Apoptosis but Induces Primary Necrosis in Neutrophils , 2005, Inflammation.
[6] R. Shaykhiev,et al. Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure. , 2005, American journal of physiology. Lung cellular and molecular physiology.
[7] A. Surprenant,et al. Pseudoapoptosis Induced by Brief Activation of ATP-gated P2X7 Receptors* , 2005, Journal of Biological Chemistry.
[8] V. Nizet,et al. Keratinocyte Production of Cathelicidin Provides Direct Activity against Bacterial Skin Pathogens , 2005, Infection and Immunity.
[9] F. Yarovinsky,et al. Mouse Cathelin-Related Antimicrobial Peptide Chemoattracts Leukocytes Using Formyl Peptide Receptor-Like 1/Mouse Formyl Peptide Receptor-Like 2 as the Receptor and Acts as an Immune Adjuvant1 , 2005, The Journal of Immunology.
[10] Xiao-tong Ma,et al. LL-37 enhances adaptive antitumor immune response in a murine model when genetically fused with M-CSFR (J6-1) DNA vaccine. , 2005, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.
[11] R. Hancock,et al. Immunomodulatory Activities of Small Host Defense Peptides , 2005, Antimicrobial Agents and Chemotherapy.
[12] M. Kagnoff,et al. Cathelicidin Mediates Innate Intestinal Defense against Colonization with Epithelial Adherent Bacterial Pathogens1 , 2005, The Journal of Immunology.
[13] D. Davidson,et al. Impact of LL‐37 on anti‐infective immunity , 2005, Journal of leukocyte biology.
[14] R. Gallo,et al. Structure-Function Relationships among Human Cathelicidin Peptides: Dissociation of Antimicrobial Properties from Host Immunostimulatory Activities , 2005, The Journal of Immunology.
[15] T. Ohtake,et al. Expression of an additional cathelicidin antimicrobial peptide protects against bacterial skin infection. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[16] Robert E W Hancock,et al. A re-evaluation of the role of host defence peptides in mammalian immunity. , 2005, Current protein & peptide science.
[17] R. Hancock,et al. Interaction and Cellular Localization of the Human Host Defense Peptide LL-37 with Lung Epithelial Cells , 2005, Infection and Immunity.
[18] Liqin Wang,et al. P2X7 receptor-mediated apoptosis of human cervical epithelial cells. , 2004, American journal of physiology. Cell physiology.
[19] Hiroshi Isogai,et al. C-terminal domain of human CAP18 antimicrobial peptide induces apoptosis in oral squamous cell carcinoma SAS-H1 cells. , 2004, Cancer letters.
[20] J. Kwak,et al. Identification of Peptides That Antagonize Formyl Peptide Receptor-Like 1-Mediated Signaling1 , 2004, The Journal of Immunology.
[21] Robert E. W. Hancock,et al. Can innate immunity be enhanced to treat microbial infections? , 2004, Nature Reviews Microbiology.
[22] M. Wewers,et al. A Novel P2X7 Receptor Activator, the Human Cathelicidin-Derived Peptide LL37, Induces IL-1β Processing and Release1 , 2004, The Journal of Immunology.
[23] R. Hancock,et al. The Human Cationic Peptide LL-37 Induces Activation of the Extracellular Signal-Regulated Kinase and p38 Kinase Pathways in Primary Human Monocytes1 , 2004, The Journal of Immunology.
[24] U. Wahn,et al. β-defensins and LL-37 in bronchoalveolar lavage fluid of patients with cystic fibrosis , 2004 .
[25] R. Gallo,et al. Postsecretory Processing Generates Multiple Cathelicidins for Enhanced Topical Antimicrobial Defense1 , 2004, The Journal of Immunology.
[26] R. Hancock,et al. The Cationic Antimicrobial Peptide LL-37 Modulates Dendritic Cell Differentiation and Dendritic Cell-Induced T Cell Polarization , 2004, The Journal of Immunology.
[27] M. Zanetti. Cathelicidins, multifunctional peptides of the innate immunity , 2004, Journal of leukocyte biology.
[28] I. Nagaoka,et al. Effect of antibacterial cathelicidin peptide CAP18/LL-37 on sepsis in neonatal rats , 2004, Pediatric Surgery International.
[29] K. Rabe,et al. The Antimicrobial Peptide LL-37 Activates Innate Immunity at the Airway Epithelial Surface by Transactivation of the Epidermal Growth Factor Receptor 1 , 2003, The Journal of Immunology.
[30] H. Simon. Neutrophil apoptosis pathways and their modifications in inflammation , 2003, Immunological reviews.
[31] S. Zahler,et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. , 2003, The Journal of clinical investigation.
[32] N. Salzman,et al. Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin , 2003, Nature.
[33] M. Ståhle-Bäckdahl,et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. , 2003, The Journal of investigative dermatology.
[34] Göran Carlsson,et al. Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study , 2002, The Lancet.
[35] Tomas Ganz,et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. , 2002, The New England journal of medicine.
[36] R. Hancock,et al. The Human Antimicrobial Peptide LL-37 Is a Multifunctional Modulator of Innate Immune Responses1 , 2002, The Journal of Immunology.
[37] K. Iwabuchi,et al. A cathelicidin family of human antibacterial peptide LL‐37 induces mast cell chemotaxis , 2002, Immunology.
[38] R. Bals,et al. Increased levels of antimicrobial peptides in tracheal aspirates of newborn infants during infection. , 2002, American journal of respiratory and critical care medicine.
[39] M. Zasloff. Antimicrobial peptides of multicellular organisms , 2002, Nature.
[40] Takaaki Ohtake,et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection , 2001, Nature.
[41] S. Edwards,et al. BCL‐2 family expression in human neutrophils during delayed and accelerated apoptosis , 2001, Journal of leukocyte biology.
[42] H. Simon,et al. Critical Role for Caspases 3 and 8 in Neutrophil But Not Eosinophil Apoptosis , 2001, International Archives of Allergy and Immunology.
[43] F. Lang,et al. CD95/CD95 ligand interactions on epithelial cells in host defense to Pseudomonas aeruginosa. , 2000, Science.
[44] Ji Ming Wang,et al. Ll-37, the Neutrophil Granule–And Epithelial Cell–Derived Cathelicidin, Utilizes Formyl Peptide Receptor–Like 1 (Fprl1) as a Receptor to Chemoattract Human Peripheral Blood Neutrophils, Monocytes, and T Cells , 2000, The Journal of experimental medicine.
[45] C. McMaster,et al. Preferential externalization of newly synthesized phosphatidylserine in apoptotic U937 cells is dependent on caspase-mediated pathways. , 2000, Biochimica et biophysica acta.
[46] A. Karlsson,et al. The synthetic chemoattractant Trp-Lys-Tyr-Met-Val-DMet activates neutrophils preferentially through the lipoxin A(4) receptor. , 2000, Blood.
[47] R. Hancock,et al. Cutting Edge: Cationic Antimicrobial Peptides Block the Binding of Lipopolysaccharide (LPS) to LPS Binding Protein1 , 2000, The Journal of Immunology.
[48] James M. Wilson,et al. Augmentation of Innate Host Defense by Expression of a Cathelicidin Antimicrobial Peptide , 1999, Infection and Immunity.
[49] L. Matrisian,et al. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. , 1999, Science.
[50] S. Hultgren,et al. Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. , 1998, Science.
[51] E. Pauwels,et al. Antibacterial activity of human neutrophil defensins in experimental infections in mice is accompanied by increased leukocyte accumulation. , 1998, The Journal of clinical investigation.
[52] Alan J. Waring,et al. Activities of LL-37, a Cathelin-Associated Antimicrobial Peptide of Human Neutrophils , 1998, Antimicrobial Agents and Chemotherapy.
[53] Junying Yuan,et al. Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis , 1998, Cell.
[54] Xiaodong Wang,et al. Bid, a Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors , 1998, Cell.
[55] P. Ehrlich. Granules of the Human Neutrophilic Polymorphonuclear Leukocyte , 1997 .
[56] R. Hancock,et al. Antiendotoxin activity of cationic peptide antimicrobial agents , 1996, Infection and immunity.
[57] J. Goldberg,et al. Role of Mutant CFTR in Hypersusceptibility of Cystic Fibrosis Patients to Lung Infections , 1996, Science.
[58] N. Hogg,et al. Neutrophil apoptosis is associated with a reduction in CD16 (Fc gamma RIII) expression. , 1994, Journal of immunology.
[59] F. Herrmann,et al. Prolongation of survival of human polymorphonuclear neutrophils by granulocyte-macrophage colony-stimulating factor is caused by inhibition of programmed cell death. , 1992, Blood.
[60] A. BØyum,et al. Separation of Leucocytes: Improved Cell Purity by Fine Adjustments of Gradient Medium Density and Osmolality , 1991, Scandinavian journal of immunology.
[61] J. Metcalf,et al. Microbicidal/cytotoxic proteins of neutrophils are deficient in two disorders: Chediak-Higashi syndrome and "specific" granule deficiency. , 1988, The Journal of clinical investigation.
[62] R. Hancock,et al. Procedure for isolation of bacterial lipopolysaccharides from both smooth and rough Pseudomonas aeruginosa and Salmonella typhimurium strains , 1983, Journal of bacteriology.